The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons
Abstract
CONTEXT: Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy. OBJECTIVE: To determine trends in prevalence of HIV-1 drug resistance among recently infected individuals in a geographic area with a high penetration of antiviral treatment. DESIGN, SETTING, AND PATIENTS: Consecutive case series of 225 patients referred to a San Francisco, Calif, hospital with recent HIV-1 infection from June 1996 through June 2001. MAIN OUTCOME MEASURE: Time trends in the prevalence of genotypic and phenotypic primary drug resistance. RESULTS: Mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) steadily increased from 0% in 1996-1997 to 12 (13.2%) in 2000-2001 (P =.01). There was 1 mutation associated with protease inhibitor resistance in 1996-1997 (2.5%) and there were 7 (7.7%) in 2000-2001 (P =.25). Genotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) initially decreased and then returned to prior levels (P =.007 for test of homogeneity). Genotypic resistance to 2 or more classes of drugs increased from 1 (2.5%) to 12 (13.2%) (P =.004), but only 1 infection (1.2%) in the latter period was resistant to all 3 classes of agents (P =.58). Primary phenotypic resistance decreased for NRTIs from 21% to 6.2% (P =.03) and increased for NNRTIs from 0 to 8 (9.9%) (P =.02). Phenotypic resistance increased for protease inhibitors from 2.6% to 6.2% (P =.32). Median time to virologic suppression (<500 copies/mL) during therapy was 12 weeks for patients with genotypic evidence of resistance compared with 5 weeks for patients with drug-sensitive infections (P =.02). CONCLUSIONS: The frequency of primary resistance to NNRTIs is increasing, although resistance to all available classes of antiretroviral therapy remains rare. Genotypic resistance testing in recently infected persons predicts time to viral suppression during therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., & Gray, R. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421303 · Cited by 3,020
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA · doi:10.1001/jama.279.12.930 · Cited by 756
Janssen, R. S. (1998) · JAMA · doi:10.1001/jama.280.1.42 · Cited by 687
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
Self-citationA Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
HIV-1 Drug Resistance in Newly Infected Individuals
Boden, D. (1999) · JAMA · doi:10.1001/jama.282.12.1135 · Cited by 466
Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390504 · Cited by 444
Self-citationDeeks, S. G., Hecht, F. M., Swanson, M., Elbeik, T., Loftus, R., Cohen, P. T., & Grant, R. M. (1999) · AIDS · doi:10.1097/00002030-199904160-00001 · Cited by 436
Self-citationA Tale of Two Futures: HIV and Antiretroviral Therapy in San Francisco
Blower, S. M., Gershengorn, H. B., & Grant, R. M. (2000) · Science · doi:10.1126/science.287.5453.650 · Cited by 390
Self-citationTransmission of antiretroviral-drug-resistant HIV-1 variants
Yerly, S., Kaiser, L., Race, E., Bru, J.-P., Clavel, F., & Perrin, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12262-6 · Cited by 389
Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection
Little, S. J. (1999) · JAMA · doi:10.1001/jama.282.12.1142 · Cited by 335
Mammano, F., Petit, C., & Clavel, F. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7632-7637.1998 · Cited by 264
Predicting the unpredictable: Transmission of drug-resistant HIV
Blower, S. M., Aschenbach, A. N., Gershengorn, H. B., & Kahn, J. O. (2001) · Nature Medicine · doi:10.1038/nm0901-1016 · Cited by 221
Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J. A., Lapidus, W. I., Schleif, W. A., Whitley, R. J., HILDEBRAND, C. S., Byrnes, V. W., Kappes, J. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310073291502 · Cited by 156
Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) · BMJ · doi:10.1136/bmj.322.7294.1087 · Cited by 154
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
Stoddart, C. A., Liegler, T. J., Mammano, F., Linquist-Stepps, V. D., Hayden, M. S., Deeks, S. G., Grant, R. M., Clavel, F., & McCune, J. M. (2001) · Nature Medicine · doi:10.1038/89090 · Cited by 136
Self-citationDeeks, S. G., Hoh, R., Grant, R. M., Wrin, T., Barbour, J. D., Narvaez, A., Cesar, D., Abe, K., Hanley, M. B., Hellmann, N. S., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/338467 · Cited by 107
Self-citationHirsch, M., Steigbigel, R. T., Staszewski, S., Mellors, J. W., Scerpella, E. G., Hirschel, B. J., Lange, J. M. A., Squires, K., Rawlins, S., Meibohm, A. R., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/314948 · Cited by 102
Winters, M. A., Schapiro, J., Lawrence, J., & Merigan, T. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5303-5306.1998 · Cited by 100
Conlon, C. P., Klenerman, P., Edwards, A. M., Larder, B. A., & Phillips, R. E. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.411 · Cited by 71
Goudsmit, J., Weverling, G. J., van der Hoek, L., de Ronde, A., Miedema, F. F., Coutinho, R. A., Lange, J. M. A., & Boerlijst, M. C. (2001) · AIDS · doi:10.1097/00002030-200111230-00011 · Cited by 29
Transmission of Zidovudine-Resistant HIV During a Bloody Fight
Ippolito, G. (1994) · JAMA · doi:10.1001/jama.1994.03520060031019 · Cited by 25
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D. E., Orenstein, J. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234683100 · Cited by 426
Metadata
- Authors
- Grant, R. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-10
- Volume
- 288
- Issue
- 2
- Pages
- 181
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2018112385
- Cited by
- 459
- References
- 26
- FWCI
- 25.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.